Skip Navigation


Brain Advance Access originally published online on September 11, 2007
Brain 2007 130(10):2554-2565; doi:10.1093/brain/awm202
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
130/10/2554    most recent
awm202v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Williams, A.
Right arrow Articles by Lubetzki, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, A.
Right arrow Articles by Lubetzki, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2007). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Semaphorin 3A and 3F: key players in myelin repair in multiple sclerosis?

Anna Williams, Gabrièle Piaton, Marie-Stéphane Aigrot, Aisha Belhadi, Marie Théaudin, Franziska Petermann, Jean-Léon Thomas, Bernard Zalc and Catherine Lubetzki

Inserm, U711, Paris, F-75013 and Université Pierre & Marie Curie, Faculté de médecine, IFR 70, Paris, France

Correspondence to: Anna Williams, Department of Clinical Neurosciences, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK E-mail: annacwilliwams{at}yahoo.co.uk

The presence of demyelinated plaques in the central nervous system is the hallmark of multiple sclerosis (MS). Some plaques remyelinate but others do not, leaving permanent damage. The reasons for this failure of repair are many, but one possible reason is the lack of migration of oligodendrocyte precursor cells to the lesion. The guidance molecules Semaphorin 3A and 3F, already known to direct oligodendroglial migration in development, may also be active in controlling oligodendrocyte precursor cell migration in MS, and hence may determine the ability of plaques to remyelinate. Here, in MS tissue and an experimental model of demyelination, we demonstrate a local source of these molecules around active demyelinating lesions, but not chronic plaques. We also provide evidence for their up-regulation at a distance from the lesion, in the neuronal cell bodies corresponding to the demyelinated axons. We propose that both of these mechanisms influence remyelination.

Key Words: multiple sclerosis; demyelination; remyelination; myelin; semaphorin

Abbreviations: ISH, in situ hybridization; LPC, lysophosphatidylcholine; MS, multiple sclerosis; NP, neuropilin; PBS, phosphate buffered saline; PFA, paraformaldehyde

Received March 19, 2007. Revised July 2, 2007. Accepted July 31, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
M. Dubois-Dalcq, A. Williams, C. Stadelmann, B. Stankoff, B. Zalc, and C. Lubetzki
From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases
Brain, July 1, 2008; 131(7): 1686 - 1700.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.